Skip to main content

Klinger Shannon Thyme's Form 4 filing

Moderna, Inc. (MRNA) · filed Dec 10, 2024

Accession no.
0001127602-24-028963
Filed
Dec 10, 2024
Trade date
Dec 6-9, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $23.6K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Klinger Shannon ThymeCIK 0001866132Officer (Chief Legal Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 6, 2024Common StockMOption exerciseAcquired+1,138–F1–20,975Direct
Dec 9, 2024Common StockSSaleDisposed−529$44.68−$23,635.7220,446Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 6, 2024Common StockMOption exerciseDisposed−1,138$0.00$02,278Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Restricted stock units convert into common stock on a one-for-one basis.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)